Lustgarten-funded clinical trial yields promising results as the Journal Nature publishes findings: Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.
Topic: Announcement, Pancreatic Cancer News, Press Releases
In May 2023, the Journal Nature published promising results from a study funded by the Pancreatic Cancer Collective (PCC), a partnership between the Lustgarten Foundation and Stand Up To Cancer. This study was the culmination of years of research leading to the critical discovery that long-term pancreatic cancer survivors have specific immune responses that the team hoped to mimic with the vaccines; half of the 16 patients treated in this study showed an immune response to the vaccine. Lead researchers Vinod Balachandran, MD, and Benjamin Greenbaum, PhD, along with their team at Memorial Sloan Kettering Cancer Center, presented these promising findings at the 2022 American Society of Clinical Oncology (ASCO) meeting.
Delve deeper into the study with insights from Andrew Rakeman, PhD, Vice President of Research at the Lustgarten Foundation, as he sheds light on Dr. Balachandran and Dr. Greenbaum’s remarkable work and explains why these findings are igniting excitement throughout the pancreatic cancer research community.
More info: recap from ASCO 2022